Annovis Bio (NYSE: ANVS) has announced a collaboration with Weave Bio to support preparation of the planned New Drug Application (NDA) for buntanetap, its investigational oral therapy for neurodegenerative diseases including Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company will use the Weave AI platform to draft, review, and manage NDA documents, while its regulatory and clinical teams retain responsibility for content, verification, and final approval of all documents submitted to the U.S. Food and Drug Administration (FDA).
The collaboration follows the completion of enrollment in Annovis’s pivotal Phase 3 AD study, which enrolled 862 biomarker-confirmed patients, exceeding the original target of 760. Annovis aims to achieve database lock for the six-month treatment period in December 2026, followed by top-line symptomatic data in March 2027, with the company seeking to have most of the NDA prepared before the data readout. This strategic move could position Annovis to file the NDA more rapidly after data readout, potentially bringing buntanetap to market sooner.
Buntanetap (formerly posiphen) is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The drug’s multi-target approach distinguishes it from many other neurodegenerative disease therapies in development, which often focus on a single protein.
The use of AI in regulatory document preparation reflects a growing trend in the life sciences industry, where companies leverage technology to manage the complex and data-intensive process of compiling an NDA. Weave Bio’s platform is designed to facilitate the drafting and review of regulatory submissions, potentially reducing the time and resources required. However, Annovis emphasizes that its own teams will maintain oversight, ensuring the accuracy and integrity of the submission.
For investors, the collaboration signals progress toward a regulatory milestone for buntanetap. The Phase 3 AD study’s enrollment success and the planned timeline for data readout and NDA preparation provide clear benchmarks to watch. If the trial results are positive, the NDA could be filed in a timely manner, advancing a potential new treatment option for AD and PD, areas of significant unmet medical need. The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.
Annovis Bio is headquartered in Malvern, Pennsylvania, and is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases. For more information, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X. To view the full press release, visit https://ibn.fm/FMiEX. This news is distributed by BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors, part of the Dynamic Brand Portfolio at IBN, which provides InvestorWire for wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
